Company / EPS (Diluted)
Caris Life Sciences, Inc. EPS (Diluted) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$13.24
FY2025
5-year range
-$13.24 / -$10.66
FY2023-FY2025
Trend
-24.2%
vs FY2024
Sector context
#157 of 159
Health Care
What the data says
Among 159 Health Care companies, Caris Life Sciences, Inc. is in the bottom 1% for eps (diluted).
Based on SEC 10-K filings.
-13.24 in FY2025.
Remained stable around $-13.24 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 159This company -$13.24 Sector average $2.35
▼
-662.9% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 24.2% year-over-year.
- Ranks #157 out of 159 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$13.24 | -24.2% |
| FY2024 | -$10.66 | +19.5% |
| FY2023 | -$13.24 | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026